This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Genocea Biosciences Inc. (developing infectious disease vaccines) has closed a $30mm Series C financing to new investors the Bill & Melinda Gates Foundation (BMGF) and CVF, and returning shareholders Polaris Venture Partners, Lux Capital, SR One, Johnson & Johnson Development Corp., Skyline Ventures, Cycad Group, Auriga Partners, MP Healthcare Ventures, and Morningside. The money will be used for ongoing development of its lead vaccine programs--Phase I/IIa GEN003 for herpes simplex virus Type 2 and preclinical GEN004 for pneumococcal infections. Funds will also support expansion of Genocea’s malaria work using its ATLAS platform in collaboration with the BMGF. The six-year-old company previously raised $23mm in its 2009 Series A and $35mm in a 2011 Series B.
Already a Strategic Transactions subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?